CommercialPrior AuthMedium impact
Rituximab Products (Rituxan®, Rituximab-abbs [Truxima®], Rituximab-arrx [Riabni™] and Rituximab-pvvr [Ruxience®])
BCBS Tennessee·TN · Rheumatology, Neurology, Dermatology +5 more·Medical Policy
Effective date
Jun 30, 2026
We identified it
Jun 17, 2026
Summary
BCBS Tennessee updated their medical policy for Rituximab products (Rituxan, Truxima, Riabni, Ruxience) for non-oncology conditions including rheumatoid arthritis, multiple sclerosis, and autoimmune disorders. The policy establishes specific prior authorization requirements, prescriber specialty restrictions, and documentation criteria for coverage approval.
Action Required
Before June 30, 2026: Billing team must implement prior authorization requirements for all Rituximab products (Rituxan, Truxima, Riabni, Ruxience) when used for non-oncology conditions. Update billing system to require specialist prescriber verification (rheumatologist, neurologist, dermatologist, etc.) based on condition. Create documentation checklists for required biomarker testing (RF, anti-CCP, CRP/ESR) for RA cases and prior medication trial records. Train staff on 12-month authorization periods and continuation criteria requiring clinical response documentation.